metastatic skin cancer
Conditions
Interventions
Intracutaneous injections of Technetium-99m-phytate (6x18.5MBq) around the tumor at lymphoscintigraphy
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who were diagnosed with metastatic skin cancer based on histopathological examination. 2. From the results of medical history, physical findings, blood, examination, and urine test, the patients who had no serious complications that could not put them under general anesthesia or lumbar anesthesia. 3. Patients who gave written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are pregnant. Patients who are breast-feeding. Patients with drug allergy to Technetium-99m -phytate. 2. Patients who did not give written informed consent. 3. Attending physician judged that the patients were inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification and localization of sentinel lymph nodes | — |
Secondary
| Measure | Time frame |
|---|---|
| Decision of the cut-off value of lymphatic transit rate indicating negative nodal metastasis | — |
Countries
Japan
Contacts
Public ContactMasao Fujiwara
Hamamatsu University School of Medicine Plastic and Reconstructive Surgery
Outcome results
None listed